TTX-030 is under clinical development by Trishula Therapeutics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TTX-030’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TTX-030 is under development for the treatment of solid tumors like pancreatic adenocarcinoma, gastric cancer and relapsed/refractory lymphoma. The drug candidate is a monoclonal antibody acts by targeting CD39. It is administered through intravenous route.
For a complete picture of TTX-030’s drug-specific PTSR and LoA scores, buy the report here.